Olaratumab

Olaratumab

Olaratumab (pronounced o-lar-a-tu-mab) is a monoclonal antibody designed for the treatment of certain types of cancer. It is also known by its trade name, Lartruvo.

Etymology

The name "Olaratumab" is derived from the Latin "Ola", meaning "wave", and "Ratumab", a common suffix for monoclonal antibodies. The "wave" signifies the drug's ability to target and attack cancer cells, similar to how a wave can sweep away objects in its path.

Usage

Olaratumab is used in combination with doxorubicin, an anthracycline chemotherapeutic, for the treatment of adult patients with soft tissue sarcoma who have not been previously treated with doxorubicin. It works by binding to the platelet-derived growth factor receptor alpha (PDGFR-α), blocking the growth of new blood vessels that tumors need to grow.

Side Effects

Common side effects of Olaratumab include nausea, fatigue, neutropenia, musculoskeletal pain, mucositis, and alopecia. Severe side effects may include infusion-related reactions and embryo-fetal toxicity.

Related Terms

• Monoclonal antibody
• Cancer
• Doxorubicin
• Anthracycline
• Sarcoma
• Platelet-derived growth factor receptor alpha
• Nausea
• Fatigue
• Neutropenia
• Musculoskeletal pain
• Mucositis
• Alopecia
• Infusion-related reactions
• Embryo-fetal toxicity

External links

• Medical encyclopedia article on Olaratumab
• Wikipedia's article - Olaratumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski